(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 July 2008 (03.07.2008)

PCT

(10) International Publication Number
WO 2008/078291 A1

(51) International Patent Classification:
C07D 487/04 (2006.01)

(21) International Application Number:
PCT/IB2007/055245

(22) International Filing Date:
20 December 2007 (20.12.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/IB2006/055019
22 December 2006 (22.12.2006) IB

(71) Applicant *(for all designated States except US)*: **ACTELION PHARMACEUTICALS LTD** [CH/CH]; Gewerbestrasse 16, CH-4123 Allschwil (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **AISSAOUI, Hamed** [FR/FR]; 4, Allée des Griottes, F-68840 Pulversheim (FR). **BOSS, Christoph** [CH/CH]; Muesmattweg 89, CH-4123 Allschwil (CH). **GUDE, Markus** [DE/CH]; Grabenring 9, CH-4123 Allschwil (CH). **KOBERSTEIN, Ralf** [DE/DE]; Jahnstrasse 7e, 79539 Lörrach (DE). **SIFFERLEN, Thierry** [FR/FR]; 22, rue de l'Eglise, F-68220 Wentzwiller (FR).


(74) Agent: **SCHAGER, Frank**; c/o Actelion Pharmaceuticals Ltd, Legal Department, Gewerbestrasse 16, CH-4123 Allschwil (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(54) Title: 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES



(I)

(57) Abstract: The invention relates to 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives of formula (I),wherein X represents CH_2 or O; R^1 represents a phenyl group, which group is independently mono-, di-, or tri-substituted wherein the substituents are independently selected from the group consisting of (C_{1-4})alkyl, (C_{1-4})alkoxy, halogen, cyano, trifluoromethoxy and trifluoromethyl; R^2 represents (C_{1-4})alkyl, (C_{1-4})alkoxy, (C_{2-4})alkenyl, halogen, cyano, hydroxymethyl, trifluoromethyl, $C(O)NR^5R^6$ or cyclopropyl; R^3 represents (C_{1-4})alkyl, (C_{1-4})alkoxy-methyl or halogen; R^4 represents (C_{1-4})alkyl; R^5 represents hydrogen or (C_{1-4})alkyl; and R^6 represents hydrogen or (C_{1-4})alkyl. The invention also relates to pharmaceutically acceptable salts of such compounds; and to the use of such compounds as medicaments; especially as orexin receptor antagonists.

WO 2008/078291 A1